Novo Nordisk beats expectations – upgrades outlook

Pharmaceutical company Novo Nordisk increased its net result in Q1 compared with the same period last year, thereby beating analyst expectations. Now, it's upgrading its outlook for 2021.
Photo: Novo Nordisk Pharmatech/PR
Photo: Novo Nordisk Pharmatech/PR

In the first three months of the year, Danish pharmaceutical company Novo Nordisk's net result increased steadily, while its top line has landed at the same level as last year, according to the firm's interim report for Q1 which was published Monday morning.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading